Ireland-incorporated Allergan (NYSE: AGN) says that the European Commission has granted Marketing Authorization for Truberzi (eluxadoline) in Europe.
As a result, Truberzi is now approved for use in the 28 countries of the European Union as well as Norway, Iceland and Liechtenstein.The approval comes following a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in July.
Truberzi is currently owned by former Allergan subsidiary Aptalis Pharmaceutical Technologies, which was sold to Teva during the marketing authorization process. Under the terms of the agreement all rights to Truberzi will be returned to Allergan in the coming months.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze